Shopping Cart
- Remove All
- Your shopping cart is currently empty
Tapinarof (Benvitimod) is targeted as a topical cream treatment for psoriasis, a chronic autoimmune skin disease.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $34 | In Stock | |
2 mg | $48 | In Stock | |
5 mg | $77 | In Stock | |
10 mg | $126 | In Stock | |
25 mg | $243 | In Stock | |
50 mg | $369 | In Stock | |
100 mg | $549 | In Stock | |
500 mg | $1,190 | In Stock | |
1 mL x 10 mM (in DMSO) | $81 | In Stock |
Description | Tapinarof (Benvitimod) is targeted as a topical cream treatment for psoriasis, a chronic autoimmune skin disease. |
Targets&IC50 | AhR:13 nM(EC50) |
In vitro | Tapinarof activates the AhR pathway through direct binding, inducing dose-dependent nuclear translocation of AhR in immortalized keratinocytes (HaCaT). |
In vivo | Tapinarof mediates its anti-inflammatory effects via the AhR pathway in IMQ-treated mice. In mice expressing AhR on a C57Bl/6 background, both Tapinarof and 6-formylindolo(3,2-b)carbazole (FICZ) significantly lower clinical inflammation scores. Conversely, AhR knockout (KO) mice exhibit no such anti-inflammatory response to Tapinarof. FICZ serves as a benchmark in these experiments, demonstrating comparable reduction in inflammation in wild-type mice, but ineffective in AhR KO mice. |
Alias | WBI 1001, GSK2894512, Benvitimod |
Molecular Weight | 254.32 |
Formula | C17H18O2 |
Cas No. | 79338-84-4 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 55 mg/mL (216.26 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.